FDA researchers identified peptides useful in the diagnosis of HIV infection. These peptides can specifically bind antibodies against HIV infection, distinguishing against antibodies elicited in response to an HIV vaccine. The increasing complexity of HIV-1 vaccine candidates has resulted in the vaccinated testing positive with currently licensed HIV-1 detection assays. Vaccine recipients may be falsely diagnosed as HIV positive and face a range of social and economic harms (e.g. employment, insurance, recruitment to the armed forces, travel, immigration, blood donations). These peptides are useful as serodiagnostic reagents to distinguish between HIV infected individuals and individuals participating in HIV vaccine trials.
|Potential Commercial Applications||Competitive Advantages|
Inventors: Surender Khurana, Hana Golding
Publications: Khurana, S., et. al. HIV-Selectest enzyme immunoassay and rapid test: ability to detect seroconversion following HIV-1 infection. J Clin Microbiol. 2010;48(1):281‐285. PMID: 19906903
- United States Patent No. 7,888,003 issued 02.12.2011
- United States Patent No. 8,722,324 issued 05.13.2014
- Corresponding international patent applications filed, and patents issued
Product Area: HIV diagnostic, post-HIV vaccine diagnostic
FDA Reference No: E-2004-030
Ken Millburne, J.D.
FDA Technology Transfer Program